Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Keytruda With an Androgen Receptor Modulator May Produce a Modest Benefit in Women with Androgen Receptor-Positive, Triple-Negative Breast Cancer
2 TGen's Dr. Daniel D. Von Hoff earns inaugural AACR scientific achievement award
3 Association Of Community Cancer Centers Releases 16 Abstracts This Fall
4 FDA Approves Reduced Frequency Durvalumab Dosing Option in NSCLC
5 City of Hope Orange County appoints oncologist, cancer researcher as physician-in-chief
6 New Dosing Option Approved for Imfinzi in NSCLC, Bladder Cancer
7 Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
8 Allard Research Chair in Oncology
9 Ravi Salgia, MD, PhD, on a 'Fast-and-Frugal' Decision Tree in NSCLC
10 Movers & Shakers, Nov. 20 | BioSpace
11 Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study
12 Lower Starting Dose of Lenvatinib in RCC Does not Meet Non-Inferiority Threshold
13 Hannah Hazard-Jenkins named director of WVU Cancer Institute
14 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist
15 Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board
16 Trillium Therapeutics Announces Formation of Scientific Advisory Board
17 Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
18 Safety, Tolerability Profile for Low-Dose Lenvatinib Is Similar to Standard Dose in RCC
19 Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine
20 A decade of success: CAR-T pioneers reflect on past, look toward future
21 Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial.
22 Chasing Cancer with Jeffrey Drebin, MD, Noopur Raje, MD & Lisa Ray
23 Nerves Keep Pancreatic Cancer Cells from Starving | NYU Langone News
24 Adam Bass to Lead Precision Cancer Medicine at Columbia University
25 Tarus Therapeutics Expands R&D Team with Appointment of Brian Schwartz, M.D. as Interim Chief Medical Officer and Head of the Scientific Advisory Board
26 Maintenance ixazomib extends PFS for subset of patients with multiple myeloma
27 Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
28 4D Pharma presents new data from two MRx0518 clinical trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | DNA RNA and Cells | News Channels
29 PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
30 Movers & Shakers, Nov. 6 | BioSpace
31 Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer and also Strengthens Scientific Advisory Board
32 Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies
33 Plus Therapeutics Announces Formation of Scientific Advisory Board
34 PDS Biotechnology Appoints Renowned Oncologist Otis Brawley, M.D. to its Board of Directors
35 Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. to its Scientific Advisory Board
36 Cancer hospitals stay open as COVID-19 cases skyrocket
37 City of Hope Physicians Present Innovative Cancer Research at ASCO20 Virtual Session
38 Other news to note for Nov. 24, 2020 | 2020-11-24
39 A New Era for Liquid Biopsy | AACC.org
40 Dabrafenib and Trametinib Show Promise in Advanced Cholangiocarcinoma
41 Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors
42 Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
43 Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
44 Journal Article Reviews Oleandrin's Antiviral Activity Against 'Enveloped' Viruses, Including its Ability to Inhibit the Virus that Causes COVID-19
45 Global CAR-T Therapy Treatment Market : Moving Towards Brighter Future | Major Giants –AbbVie Inc, Adaptimmune, Amgen Inc, Atara Biotherapeutics
46 Gene Therapy Market Trends Research, High Growth 36.1% CAGR, Industry Share, Trends and Key Trends A
47 People in the News: New Appointments at Natera, Quanterix, Sophia Genetics, More
48 Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
49 Soteria Biotherapeutics Announces Scientific Advisory Board
50 Introduction to PET PSMA Gallium-68 PSMA-11 for Diagnostic Imaging of Prostate Cancer
51 Real-World Evidence Makes Its Mark in Managed Care
52 Why hope is in our hands for cancer care in 2020
53 Prior PD-1 Blockade Did Not Appear to Influence the Severity of COVID-19 in Patients With Lung Cancer
54 City of Hope Opens Its First Orange County Location, Ushering in New Era of Cancer Care
55 Infigratinib Appears Active Across All Lines of Treatment in Patients With Advanced Bladder Cancer
56 Synthetic Lethality-Based Drugs and Targets Market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis
57 Model predicts immunotherapy response in colon and GI cancers
58 PSMA-Based Diagnostic and Theranostic Strategies in Metastatic Prostate Cancer
59 This Biotech Is Up 1,500% This Year. Can It Make You Rich in 2021?
60 FDA pilot program to communicate patient reported outcomes from cancer clinical trials
61 Payer Coverage for Liquid Biopsies Improves, but Gaps Remain, Study in JNCCN Finds
62 Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
63 Wearbale Injectors Market : Moving Towards Brighter Future | Major Giants –Amgen Inc., Medtronic, Insulet Corporation, Ypsomed, BD, Cellnovo
64 Targeting KRAS in Colorectal Cancer Is an Ongoing Medical Challenge
65 Movers & Shakers for Nov. 22
66 ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in Combination with Atezolizumab as First-Line Therapy...
67 Combination Therapy With Cabozantinib and Atezolizumab Gains Foothold in Urothelial Carcinoma
68 Drug Duo Is Promising in Older Patients With Advanced HCC
69 Study shows new way of identifying tumor response to immunotherapy
70 ASCO announces 2020 awards – The Cancer Letter
71 CRISPR-based treatment successfully targets aggressive cancers in vivo
72 OncMadness: Meet the Blue Ribbon Panel
73 COVID-19: What People Living with Metastatic Breast Cancer Need to Know
74 GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies
75 AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
76 ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advance...
77 Cabozantinib Plus Atezolizumab Shows Promising Clinical Activity in Advanced Clear Cell Renal Cell Carcinoma
78 Patton named CEO of OneOncology
79 COVID-19 Update: State Awards Nearly $10M in Federal Funds for COVID-19 Wastewater Surveillance, City Club Apartments Get $78.5M Bridge Loan for Detroit Development, and More
80 Dr. Pal on the Background of the COSMIC-021 Trial in Urothelial Cancer
81 AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program
82 Yale Cancer Center Awarded NIH SPORE for Head and Neck Cancer Research
83 Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
84 MD Anderson's Patrick Hwu to helm Moffitt Cancer Center; After Rockwell Medical ouster, Robert Chioini gets another chance to lead
85 Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Small Molecules | News Channels
86 Here's a $200M China startup idea — if you can read beyond the big words
87 Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.
88 dr-fakih-on-the-safety-profile-of-amg-510-in-kras-g12c-mutated-crc
89 OncLive® Presents State of the Science Summit™ on Gastrointestinal Malignancies
90 Emotional Distress During the COVID-19 Pandemic: Psycho-Oncology Perspective
91 First new drug in years reduces recurrence in high risk HR+ early breast cancer
92 Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology
93 Kelvin Lee named director of IU Melvin and Bren Simon Comprehensive Cancer Center
94 FDA Approves Pembrolizumab for TMB-High Solid Tumors
95 C. Kent Osborne steps down as director of Dan L Duncan Comprehensive Cancer Center
96 Expert in Early Phase Therapeutics Joins NYU Langone Health as Associate Director for Clinical Research at Perlmutter Cancer Center
97 Phase 3 study of three-drug regimen for biliary tract cancer exceeds enrollment goal
98 Personalized Cancer Therapy Improves Outcomes in Advanced Disease, Says Study
99 Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCC
100 MD Anderson, Allogene partner on development of allogeneic CAR T-cell therapies